167 related articles for article (PubMed ID: 19034272)
1. Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imaging.
Vassileva V; Moriyama EH; De Souza R; Grant J; Allen CJ; Wilson BC; Piquette-Miller M
Br J Cancer; 2008 Dec; 99(12):2037-43. PubMed ID: 19034272
[TBL] [Abstract][Full Text] [Related]
2. Novel biocompatible intraperitoneal drug delivery system increases tolerability and therapeutic efficacy of paclitaxel in a human ovarian cancer xenograft model.
Vassileva V; Grant J; De Souza R; Allen C; Piquette-Miller M
Cancer Chemother Pharmacol; 2007 Nov; 60(6):907-14. PubMed ID: 17375303
[TBL] [Abstract][Full Text] [Related]
3. Sustained release paclitaxel-loaded core-shell-structured solid lipid microparticles for intraperitoneal chemotherapy of ovarian cancer.
Han S; Dwivedi P; Mangrio FA; Dwivedi M; Khatik R; Cohn DE; Si T; Xu RX
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):957-967. PubMed ID: 30892967
[TBL] [Abstract][Full Text] [Related]
4. Poly(ethylene glycol)-block-poly(ε-caprolactone) micelles for combination drug delivery: evaluation of paclitaxel, cyclopamine and gossypol in intraperitoneal xenograft models of ovarian cancer.
Cho H; Lai TC; Kwon GS
J Control Release; 2013 Feb; 166(1):1-9. PubMed ID: 23246471
[TBL] [Abstract][Full Text] [Related]
5. Development and evaluation of novel tumor-targeting paclitaxel-loaded nano-carriers for ovarian cancer treatment: in vitro and in vivo.
Yao S; Li L; Su XT; Wang K; Lu ZJ; Yuan CZ; Feng JB; Yan S; Kong BH; Song K
J Exp Clin Cancer Res; 2018 Feb; 37(1):29. PubMed ID: 29478415
[TBL] [Abstract][Full Text] [Related]
6. Paclitaxel-loaded hyaluronan solid nanoemulsions for enhanced treatment efficacy in ovarian cancer.
Kim JE; Park YJ
Int J Nanomedicine; 2017; 12():645-658. PubMed ID: 28176896
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models.
Oliva P; Decio A; Castiglioni V; Bassi A; Pesenti E; Cesca M; Scanziani E; Belotti D; Giavazzi R
Br J Cancer; 2012 Jul; 107(2):360-9. PubMed ID: 22713663
[TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal chemotherapy of ovarian cancer by hydrogel depot of paclitaxel nanocrystals.
Sun B; Taha MS; Ramsey B; Torregrosa-Allen S; Elzey BD; Yeo Y
J Control Release; 2016 Aug; 235():91-98. PubMed ID: 27238443
[TBL] [Abstract][Full Text] [Related]
9. Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer.
Vassileva V; Allen CJ; Piquette-Miller M
Mol Cancer Ther; 2008 Mar; 7(3):630-7. PubMed ID: 18347149
[TBL] [Abstract][Full Text] [Related]
10. Hyaluronic acid-based hydrogel for regional delivery of paclitaxel to intraperitoneal tumors.
Bajaj G; Kim MR; Mohammed SI; Yeo Y
J Control Release; 2012 Mar; 158(3):386-92. PubMed ID: 22178261
[TBL] [Abstract][Full Text] [Related]
11. Tumor-penetrating microparticles for intraperitoneal therapy of ovarian cancer.
Lu Z; Tsai M; Lu D; Wang J; Wientjes MG; Au JL
J Pharmacol Exp Ther; 2008 Dec; 327(3):673-82. PubMed ID: 18780831
[TBL] [Abstract][Full Text] [Related]
12. RGD-based strategies for improving antitumor activity of paclitaxel-loaded liposomes in nude mice xenografted with human ovarian cancer.
Zhao H; Wang JC; Sun QS; Luo CL; Zhang Q
J Drug Target; 2009 Jan; 17(1):10-8. PubMed ID: 19016068
[TBL] [Abstract][Full Text] [Related]
13. Liposomal paclitaxel induces apoptosis, cell death, inhibition of migration capacity and antitumoral activity in ovarian cancer.
Faria RS; de Lima LI; Bonadio RS; Longo JPF; Roque MC; de Matos Neto JN; Moya SE; de Oliveira MC; Azevedo RB
Biomed Pharmacother; 2021 Oct; 142():112000. PubMed ID: 34426249
[TBL] [Abstract][Full Text] [Related]
14. Engineered multifunctional biodegradable hybrid microparticles for paclitaxel delivery in cancer therapy.
Dwivedi P; Han S; Mangrio F; Fan R; Dwivedi M; Zhu Z; Huang F; Wu Q; Khatik R; Cohn DE; Si T; Hu S; Sparreboom A; Xu RX
Mater Sci Eng C Mater Biol Appl; 2019 Sep; 102():113-123. PubMed ID: 31146981
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of a backbone biodegradable multiblock HPMA copolymer nanocarrier for the systemic delivery of paclitaxel.
Zhang R; Luo K; Yang J; Sima M; Sun Y; Janát-Amsbury MM; Kopeček J
J Control Release; 2013 Feb; 166(1):66-74. PubMed ID: 23262201
[TBL] [Abstract][Full Text] [Related]
16. Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer.
Kinoshita J; Fushida S; Tsukada T; Oyama K; Watanabe T; Shoji M; Okamoto K; Nakanuma S; Sakai S; Makino I; Furukawa H; Hayashi H; Nakamura K; Inokuchi M; Nakagawara H; Miyashita T; Tajima H; Takamura H; Ninomiya I; Fujimura T; Masakazu Y; Hirakawa K; Ohta T
Oncol Rep; 2014 Jul; 32(1):89-96. PubMed ID: 24859429
[TBL] [Abstract][Full Text] [Related]
17. Anticancer activity of the intraperitoneal-delivered DFP-10825, the cationic liposome-conjugated RNAi molecule targeting thymidylate synthase, on peritoneal disseminated ovarian cancer xenograft model.
Iizuka K; Jin C; Eshima K; Hong MH; Eshima K; Fukushima M
Drug Des Devel Ther; 2018; 12():673-683. PubMed ID: 29636601
[TBL] [Abstract][Full Text] [Related]
18. Impact of intraperitoneal, sustained delivery of paclitaxel on the expression of P-glycoprotein in ovarian tumors.
Ho EA; Soo PL; Allen C; Piquette-Miller M
J Control Release; 2007 Jan; 117(1):20-7. PubMed ID: 17113177
[TBL] [Abstract][Full Text] [Related]
19. Differential activation of NF-κB signaling is associated with platinum and taxane resistance in MyD88 deficient epithelial ovarian cancer cells.
Gaikwad SM; Thakur B; Sakpal A; Singh RK; Ray P
Int J Biochem Cell Biol; 2015 Apr; 61():90-102. PubMed ID: 25681684
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel-loaded expansile nanoparticles improve survival following cytoreductive surgery in pleural mesothelioma xenografts.
Chu NQ; Liu R; Colby A; de Forcrand C; Padera RF; Grinstaff MW; Colson YL
J Thorac Cardiovasc Surg; 2020 Sep; 160(3):e159-e168. PubMed ID: 32044093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
